Keytruda: India's New Cancer Warrior

Keytruda, known scientifically as pembrolizumab, is an advanced immunotherapy drug now significantly impacting cancer care in India. Unlike traditional chemotherapy, Keytruda harnesses the patient's own immune system to fight cancer cells.

This innovative therapy works by blocking the PD-1 pathway, which cancer cells use to evade detection. By deactivating this 'off switch,' Keytruda reactivates T-cells, enabling them to recognize and destroy tumors more effectively.

In India, Keytruda has received approval for 14 indications spanning eight distinct cancer types. These include non-small cell lung cancer, melanoma, various head and neck cancers, cervical cancer, triple-negative breast cancer, and renal cell carcinoma, among others.

The drug offers substantial benefits, including improved survival rates and significant tumor shrinkage, with potential for long-term remission due to immune memory.

Keytruda is administered via IV drip and is available in India at a cost of approximately Rs. 1.5 lakh to Rs. 2.16 lakh per 100mg/4ml vial.

While highly effective, Keytruda can cause immune-related adverse events, ranging from mild fatigue and rash to more serious inflammation of organs like the lungs or liver. Close medical monitoring is essential for patients undergoing treatment.